PL369027A1 - Zastosowanie konkretnej dawki fondaparynuksu soduw leczeniu OZW - Google Patents

Zastosowanie konkretnej dawki fondaparynuksu soduw leczeniu OZW

Info

Publication number
PL369027A1
PL369027A1 PL02369027A PL36902702A PL369027A1 PL 369027 A1 PL369027 A1 PL 369027A1 PL 02369027 A PL02369027 A PL 02369027A PL 36902702 A PL36902702 A PL 36902702A PL 369027 A1 PL369027 A1 PL 369027A1
Authority
PL
Poland
Prior art keywords
acs
treatment
specific dose
fondaparinux sodium
fondaparinux
Prior art date
Application number
PL02369027A
Other languages
English (en)
Other versions
PL206008B1 (pl
Inventor
Anthonie Wilhelmus Arnold Lensing
Original Assignee
Sanofi-Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8181220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL369027(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi-Synthelabo filed Critical Sanofi-Synthelabo
Publication of PL369027A1 publication Critical patent/PL369027A1/pl
Publication of PL206008B1 publication Critical patent/PL206008B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
PL369027A 2001-11-13 2002-11-07 Zastosowanie konkretnej dawki pentasacharydu, O-metylo-(2-deoksy-2-sulfoamino -6-O-sulfo-α-D-glukopiranozylo) -(1→4)-O-(β-D-glukopiranozylo kwasu uronowego) -(1→4)-O-(2-deoksy-2-sulfoamino-3,6-di-O-sulfo-α-D-glukopiranozylo)-(1→4)-O- (2-O-sulfo-α-L-idopiranozylo kwasu uronowego) - (1→4) -2-deoksy-2-sulfoamino-6-O-sulfo-α-D-glukopiranozydu w leczeniu ostrych zespołów wieńcowych PL206008B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01204323 2001-11-13

Publications (2)

Publication Number Publication Date
PL369027A1 true PL369027A1 (pl) 2005-04-18
PL206008B1 PL206008B1 (pl) 2010-06-30

Family

ID=8181220

Family Applications (1)

Application Number Title Priority Date Filing Date
PL369027A PL206008B1 (pl) 2001-11-13 2002-11-07 Zastosowanie konkretnej dawki pentasacharydu, O-metylo-(2-deoksy-2-sulfoamino -6-O-sulfo-α-D-glukopiranozylo) -(1→4)-O-(β-D-glukopiranozylo kwasu uronowego) -(1→4)-O-(2-deoksy-2-sulfoamino-3,6-di-O-sulfo-α-D-glukopiranozylo)-(1→4)-O- (2-O-sulfo-α-L-idopiranozylo kwasu uronowego) - (1→4) -2-deoksy-2-sulfoamino-6-O-sulfo-α-D-glukopiranozydu w leczeniu ostrych zespołów wieńcowych

Country Status (37)

Country Link
US (1) US20040248848A1 (pl)
EP (1) EP1446131B1 (pl)
JP (1) JP4523276B2 (pl)
KR (1) KR20050044318A (pl)
CN (1) CN1602197A (pl)
AP (1) AP1820A (pl)
AR (1) AR037291A1 (pl)
AT (1) ATE361753T1 (pl)
AU (1) AU2002351915B2 (pl)
BR (1) BR0212915A (pl)
CA (1) CA2465776A1 (pl)
CO (1) CO5580790A2 (pl)
CY (1) CY1106765T1 (pl)
DE (1) DE60220084T2 (pl)
DK (1) DK1446131T3 (pl)
EA (1) EA007325B1 (pl)
EC (1) ECSP045041A (pl)
ES (1) ES2287343T3 (pl)
GE (1) GEP20074097B (pl)
HK (1) HK1070561A1 (pl)
HR (1) HRP20040303B1 (pl)
HU (1) HU228959B1 (pl)
IL (2) IL161114A0 (pl)
IS (1) IS2484B (pl)
MA (1) MA27071A1 (pl)
ME (2) ME00229B (pl)
MX (1) MXPA04003045A (pl)
NO (1) NO20041320L (pl)
NZ (1) NZ552129A (pl)
PE (1) PE20030740A1 (pl)
PL (1) PL206008B1 (pl)
PT (1) PT1446131E (pl)
RS (1) RS50906B (pl)
SI (1) SI1446131T1 (pl)
UA (1) UA80399C2 (pl)
WO (1) WO2003041722A1 (pl)
ZA (1) ZA200402464B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090075910A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched fondaparinux
AU2016235662B2 (en) * 2015-03-20 2020-07-30 Aarhus Universitet Inhibitors of PCSK9 for treatment of lipoprotein metabolism disorders
US10688249B2 (en) * 2015-06-11 2020-06-23 Virchow Biotech Pvt. Ltd. Multiple dose pharmaceutical compositions containing heparin and/or heparin-like compounds and devices and methods for delivering the same
CN107595769A (zh) * 2017-10-23 2018-01-19 上海博悦生物科技有限公司 一种磺达肝癸钠注射液组合物的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.
CA2199642C (en) * 1997-03-10 2001-05-08 Roger Cariou Compositions containing an association of aspirin and an anti-xa oligosaccharide and use of an anti-xa oligosaccharide optionally in combination with aspirin
FR2764511B1 (fr) * 1997-06-13 2000-09-08 Sanofi Sa Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire
US20040087543A1 (en) * 2002-04-25 2004-05-06 Zachary Shriver Methods and products for mucosal delivery

Also Published As

Publication number Publication date
SI1446131T1 (sl) 2007-10-31
CA2465776A1 (en) 2003-05-22
AR037291A1 (es) 2004-11-03
AP1820A (en) 2008-01-11
NO20041320L (no) 2004-06-14
MEP1108A (en) 2011-02-10
ZA200402464B (en) 2005-06-29
HK1070561A1 (en) 2005-06-24
EA200400382A1 (ru) 2004-10-28
CO5580790A2 (es) 2005-11-30
RS50906B (sr) 2010-08-31
EA007325B1 (ru) 2006-08-25
EP1446131A1 (en) 2004-08-18
ATE361753T1 (de) 2007-06-15
IS7199A (is) 2004-03-29
PE20030740A1 (es) 2003-08-28
RS26704A (en) 2007-02-05
ME00229B (me) 2011-10-10
HUP0401462A2 (en) 2006-02-28
PL206008B1 (pl) 2010-06-30
BR0212915A (pt) 2004-10-13
AU2002351915B2 (en) 2007-11-29
HRP20040303A2 (en) 2004-10-31
US20040248848A1 (en) 2004-12-09
HU228959B1 (en) 2013-07-29
HUP0401462A3 (en) 2006-04-28
EP1446131B1 (en) 2007-05-09
JP2005509007A (ja) 2005-04-07
IL161114A (en) 2010-11-30
NZ552129A (en) 2008-04-30
HRP20040303B1 (en) 2012-02-29
CY1106765T1 (el) 2012-05-23
DE60220084D1 (de) 2007-06-21
UA80399C2 (en) 2007-09-25
MA27071A1 (fr) 2004-12-20
IL161114A0 (en) 2004-08-31
AP2004003014A0 (en) 2004-06-30
ES2287343T3 (es) 2007-12-16
ECSP045041A (es) 2004-04-28
JP4523276B2 (ja) 2010-08-11
DE60220084T2 (de) 2008-01-10
PT1446131E (pt) 2007-08-07
IS2484B (is) 2008-12-15
MXPA04003045A (es) 2005-06-20
DK1446131T3 (da) 2007-09-10
CN1602197A (zh) 2005-03-30
WO2003041722A1 (en) 2003-05-22
GEP20074097B (en) 2007-05-10
KR20050044318A (ko) 2005-05-12

Similar Documents

Publication Publication Date Title
IL196301A0 (en) Medicament for the treatment of hapatitis c
IL157425A0 (en) Treatment of solid tumours with paramycin derivatives
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
HUP0500424A2 (en) Combination therapy for the treatment of cancer
EP1221976A4 (en) IFN-GAMA IN LOW DOSAGE FOR TREATING DISEASES
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
GB0001710D0 (en) Therapeutic treatment
HK1070561A1 (en) Use of specific dose of fandaparinux sodium for the treatment of acs
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
LT1496918T (lt) Natrio meta-arsenito naudojimas navikams gydyti
IL155237A0 (en) Combination therapy for the treatment of estrogen-sensitive disease
AU2096002A (en) Therapeutic treatment
GB0119370D0 (en) Therapeutic agent
GB9904252D0 (en) Composition for the treatment of pain
EP1451308A4 (en) THERAPEUTIC USE OF AZIRIDINO COMPOUNDS
GB0127271D0 (en) Medical treatment
GB0128813D0 (en) Medical treatment
GB0127267D0 (en) Medical treatment
GB0106983D0 (en) Medical treatment
GB0118977D0 (en) New medical treatment
GB0105097D0 (en) Treatment of technetium
GB0104615D0 (en) Treatment of technetium
GB0130191D0 (en) Therapeutic treatment

Legal Events

Date Code Title Description
RECP Rectifications of patent specification